Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

102.35EUR
19 Sep 2019
Change (% chg)

-- (--)
Prev Close
€102.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
461,081
52-wk High
€103.15
52-wk Low
€85.06

Latest Key Developments (Source: Significant Developments)

Merck Receives FDA's Breakthrough Tag For Tepotinib Lung Cancer Therapy
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - Merck Kgaa ::ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR INVESTIGATIONAL THERAPY TEPOTINIB IN PATIENTS WITH METASTATIC NSCLC WITH METEX14 SKIPPING ALTERATIONS.INVESTIGATIONAL ORAL MET INHIBITOR HAS PREVIOUSLY RECEIVED SAKIGAKE 'FAST-TRACK' REGULATORY DESIGNATION IN JAPAN.MET EXON 14 SKIPPING ALTERATIONS AND MET AMPLIFICATIONS ARE PRESENT IN 3-5% OF NON-SMALL CELL LUNG CANCER PATIENTS AND CORRELATE WITH POOR PROGNOSIS.DESIGNATION IS BASED ON DATA FROM ONGOING VISION STUDY, WHICH SHOWED PRELIMINARY CLINICAL EVIDENCE FOR TEPOTINIB IN METASTATIC NSCLC HARBORING METEX14 SKIPPING ALTERATIONS.  Full Article

Merck KGaA Announces Start Of Phase III Evobrutinib Trials
Tuesday, 10 Sep 2019 

Sept 10 (Reuters) - Merck KGaA ::ANNOUNCES INITIATION OF TWO GLOBAL PIVOTAL PHASE III TRIALS (EVOLUTION RMS 1 AND 2) STUDYING EFFICACY AND SAFETY OF EVOBRUTINIB.EVOBRUTINIB ENTERING PHASE III TRIALS FOLLOWING RESULTS OF PHASE II CLINICAL TRIAL, WHICH MET ITS PRIMARY ENDPOINT OVER 24 WEEKS OF TREATMENT.  Full Article

Merck KGaA Says Enrolling Patients In Phase II Insight 2 Study Investigating Tepotinib
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Merck KGaA ::MERCK KGAA - ENROLLING PATIENTS IN PHASE II INSIGHT 2 STUDY INVESTIGATING TEPOTINIB IN COMBINATION WITH TKI OSIMERTINIB.MERCK KGAA - ANNOUNCES UPDATED RESULTS FOR INVESTIGATIONAL THERAPY TEPOTINIB PRESENTED AT WCLC 2019.MERCK KGAA - RESULTS INCLUDE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL DATA FROM PHASE IB/II INSIGHT STUDY.  Full Article

Merck KGaA and Broad Institute Announce CRISPR License Framework to Encourage Innovation
Thursday, 18 Jul 2019 

July 18 (Reuters) - Merck KGaA ::MERCK KGAA - CO, BROAD INSTITUTE OF MIT & HARVARD ANNOUNCED AGREEMENT BETWEEN BROAD INSTITUTE & LIFE SCIENCE BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.MERCK KGAA - AGREEMENT TO OFFER NON-EXCLUSIVE LICENSES TO CRISPR INTELLECTUAL PROPERTY UNDER RESPECTIVE CONTROL FOR COMMERCIAL RESEARCH, PRODUCT DEVELOPMENT.  Full Article

Germany’s Merck Pleased With Intermolecular’s Shareholder Approval of Takeover
Thursday, 18 Jul 2019 

July 18 (Reuters) - Merck KGaA::VERY PLEASED WITH THIS POSITIVE DEVELOPMENT OF INTERMOLECULAR’S STOCKHOLDERS APPROVING OUR ACQUISITION PROPOSAL.TRANSACTION IS EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.  Full Article

Merck KGaA Says FDA Approves Renal Cell Carcinoma Combination Therapy
Wednesday, 15 May 2019 

May 15 (Reuters) - Merck KGaA ::PHASE III STUDY SHOWED A 31% SIGNIFICANT REDUCTION IN THE RISK OF DISEASE PROGRESSION OR DEATH IN COMBINATION WITH SUNITINIB IN PATIENTS WITH ADVANCED RCC AND A PROGRESSION-FREE SURVIVAL (PFS) PROLONGED BY 5.4 MONTHS.COMBINATION APPROVED BASED ON PHASE III DATA IN AN OVERALL POPULATION THAT INCLUDED PATIENTS REGARDLESS OF PD-L1 EXPRESSION AND ACROSS FAVORABLE, INTERMEDIATE AND POOR PROGNOSTIC GROUPS.FDA GRANTS APPROVAL FOR COMBINATION OF BAVENCIO® (AVELUMAB) PLUS AXITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.  Full Article

Merck Says Signs Definitive Agreement To Buy Intermolecular
Monday, 6 May 2019 

May 6 (Reuters) - MERCK KGAA ::SIGNS DEFINITIVE AGREEMENT TO ACQUIRE INTERMOLECULAR FOR $1.20 PER SHARE IN AN ALL CASH TRANSACTION.TRANSACTION EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.ACQUISITION TO STRENGTHEN SEMICONDUCTOR TECHNOLOGY OFFERING.  Full Article

Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction
Monday, 6 May 2019 

May 6 (Reuters) - Intermolecular Inc ::INTERMOLECULAR TO BE ACQUIRED BY MERCK KGAA, DARMSTADT, GERMANY FOR $1.20 PER SHARE IN AN ALL CASH TRANSACTION.INTERMOLECULAR INC - DEAL FOR APPROXIMATELY $62 MILLION.INTERMOLECULAR INC - ACQUISITION HAS BEEN UNANIMOUSLY APPROVED BY INTERMOLECULAR'S BOARD OF DIRECTORS AND EXECUTIVE BOARD OF MERCK KGAA, DARMSTADT, GERMANY.INTERMOLECULAR INC - MERCK KGAA, DARMSTADT, GERMANY, WILL ACQUIRE INTERMOLECULAR THROUGH ITS WHOLLY OWNED SUBSIDIARY EMD GROUP HOLDING II, INC.  Full Article

Merck KGaA And European Space Agency Sign Letter Of Intent
Thursday, 2 May 2019 

May 2 (Reuters) - Merck KGaA ::MERCK AND THE EUROPEAN SPACE AGENCY (ESA) TODAY SIGNED A LETTER OF INTENT TO EXTEND BY A FURTHER TWO YEARS THEIR COOPERATION AGREEMENT FROM 2016..  Full Article

Merck KGaA: We Will Generate 2 Bln Euros A Year With New Drugs From 2022
Friday, 26 Apr 2019 

April 26 (Reuters) - Merck KGaA CEO Stefan Oschmann at company's annual general meeting ::CONFIRMS 2019 OUTLOOK OF MODERATE ORGANIC REVENUE GROWTH AND STRONG ORGANIC ADJUSTED EBITDA GROWTH - AGM SPEECH.THERE WILL BE ANNUAL REVENUES OF 2 BILLION EUR GENERATED BY NEW DRUGS FROM 2022.OUR LIFE SCIENCES BUSINESS SHOULD GROW FASTER THAN THE MARKET.CO TARGETS ANNUAL REVENUE GROWTH IN ELECTRONICS BUSINESS OF 2 TO 3 PERCENT, ADJUSTED EBITDA MARGIN OF AROUND 30 PERCENT.LOW POINT IN ELECTRONICS BUSINESS SHOULD BE REACHED THIS YEAR.  Full Article

Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

FRANKFURT, Sept 11 Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation.